Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomized, Double-blind, Placebo-controlled Cross Over Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)

Trial Profile

A Prospective, Randomized, Double-blind, Placebo-controlled Cross Over Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Feb 2019

At a glance

  • Drugs Everolimus (Primary)
  • Indications Seizures
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Feb 2019 Planned initiation date changed from 1 Jan 2019 to 1 Mar 2019.
    • 08 Jan 2019 Planned initiation date changed from 1 Jun 2018 to 1 Jan 2019.
    • 17 May 2018 Planned End Date changed from 31 Mar 2019 to 30 Apr 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top